Findings from St. Louis University Provide New Insights into Cancer Gene Therapy (Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news originating from St. Louis, Missouri, by NewsRx correspondents, research stated, "Human adenovirus (HAdV) vectors are intensely investigated for virotherapy of a wide variety of human cancers. Here, we have evaluated the effect of two apoptogenic HAdV5 vectors in an immunocompetent Syrian hamster animal model of head and neck cancer."
Our news journalists obtained a quote from the research from St. Louis University, "We established two cell lines of hamster cheek pouch squamous cell carcinomas induced by treatment with 9,10-dimethyl-1,2-benzanthracene. These cell lines when infected with HAdV5 mutants. Ip11w and Ip11w/Delta 55 K (which are defective in the expression of either ElB-19 K alone or both ElB-19 K and ElB-55 K proteins) exhibited enhanced apoptotic and cytotoxic responses. The cheek pouch tumor cells transplanted either subcutaneously at the flanks or in the cheek pouches of hamsters readily formed tumors. Intratumoral administration of HAdV5-E1B mutants efficiently suppressed the growth of tumors at both sites. Histological examination of orthotopic tumors revealed reduced vascularity and the expression of the viral fiber antigen in virus-administered cheek pouch tumors. These tumors also exhibited increased caspase-3 levels suggesting that virus-induced apoptosis may contribute to tumor growth suppression."
According to the news editors, the research concluded: "Our results suggest that the apoptogenic HAdV5 vectors may have utility for the treatment of human head and neck cancers."
For more information on this research see: Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model. Cancer Gene Therapy, 2014;21(6):228-237. Cancer Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)
The news correspondents report that additional information may be obtained from S. Vijayalingam, St. Louis University, Center Canc, Dept. of Otolaryngol Head & Neck Surg, St Louis, MO 63104, United States. Additional authors for this research include M. Kuppuswamy, T. Subramanian, F.F. Strebeck, C.L. West, M. Varvares and G. Chinnadurai (see also Biotechnology).
Keywords for this news article include: St. Louis, Missouri, United States, North and Central America, Biotechnology
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC